Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Short-term Investments (2016 - 2017)

Adma Biologics (ADMA) has disclosed Short-term Investments for 2 consecutive years, with $1.5 million as the latest value for Q4 2017.

  • For the quarter ending Q4 2017, Short-term Investments changed N/A year-over-year to $1.5 million, compared with a TTM value of $1.5 million through Dec 2017, changed N/A, and an annual FY2017 reading of $1.5 million, changed N/A over the prior year.
  • Short-term Investments was $1.5 million for Q4 2017 at Adma Biologics, up from $845389.0 in the prior quarter.
  • Across five years, Short-term Investments topped out at $6.4 million in Q4 2015 and bottomed at $245000.0 in Q1 2017.